Skip to content
Screener

Mesa Laboratories MLAB Biopharmaceutical Development — Goodwill Foreign Currency Translation Gain Loss

Other segment segments

Clinical Genomics
$39K-71.1%

Similar metrics at other companies

Constellation Brands logo
STZConstellationwinesandspirits — Goodwill Foreign Currency Translation Gain Loss
$43.3M
IDT Corporation logo
IDTNet2phone — Goodwill Foreign Currency Translation Gain Loss
$19.25K+450%
Restoration Hardware logo
RHRH — Goodwill Foreign Currency Translation Gain Loss
$3K-94.9%
Lesaka Technologies, Inc. logo
LSAKConsumer — Goodwill Foreign Currency Translation Gain Loss
$256K+138%
Lesaka Technologies, Inc. logo
LSAKEnterprise — Goodwill Foreign Currency Translation Gain Loss
$584K
Lesaka Technologies, Inc. logo
LSAKMerchant — Goodwill Foreign Currency Translation Gain Loss
$7.58M+144%

Other financials

Income statement

See full
Revenue$60.1M+1.0%
Gross profit$31.2M-0.5%
Operating income-$664.0K+85.5%
Net income$2.8M-40.3%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$30.7M+44.3%
Total debt$78.5M-52.9%
Total equity$188.8M+9.4%
Total assets$419.2M-3.8%

Cash flow

See full
Operating cash flow$14.7M+678%
CapEx$559.0K-44.6%
Free cash flow$14.2M+1,504%

Valuation

See full
Market cap$574.42M+70.9%
Enterprise value$622.2M+28.9%
P/E42×
P/S2.3×+0.9×

Profitability

See full
Gross margin56.8%
Operating margin2.3%
Net margin1.5%+0.8pp
FCF margin21.2%+7.3pp

Returns & leverage

See full
Return on equity2.2%+1.1pp
Debt / equity0.4×-0.6×
Current ratio1.8×+1.1×

Where this comes from

Reported directly by Mesa Laboratories in its filing.

Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.

The source filing: Mesa Laboratories’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 5:17 PM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0001437749-26-026808
Line itemSterilization and Disinfection ControlBiopharmaceutical DevelopmentCalibration SolutionsClinical GenomicsTotal
March 31, 2026$82,810$49,666$37,266$17,121$186,863
Effect of foreign currency translation(273)(585)(6)39(825)
June 30, 2026$82,537$49,081$37,260$17,160$186,038

Document

FAQ

What is Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss?
Mesa Laboratories (MLAB) reported biopharmaceutical development — goodwill foreign currency translation gain loss of -$585K in Q2 2026.
How has Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss changed year-over-year?
Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss decreased by 135.8% year-over-year, from $1.63M to -$585K.
What does biopharmaceutical development — goodwill foreign currency translation gain loss mean?
Reflects the impact of fluctuations in foreign exchange rates on the carrying value of goodwill denominated in currencies other than the reporting currency for the Biopharmaceutical Development segment. This metric highlights the sensitivity of the segment's intangible asset valuations to global macroeconomic volatility. It is a non-cash adjustment that impacts the balance sheet rather than operational cash flow.

Ask your AI about Mesa Laboratories's biopharmaceutical development — goodwill foreign currency translation gain loss.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude